Moreover, the 36-month beta value for QTTB is -0.38. Analysts have varying opinions on the stock, with 2 analysts rating it as a “buy,” 3 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for QTTB is 4.30M and currently, short sellers hold a 15.96% of that float. On November 15, 2024, QTTB’s average trading volume was 109.02K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
QTTB) stock’s latest price update
The stock price of Q32 Bio Inc (NASDAQ: QTTB) has dropped by -10.32 compared to previous close of 39.73. Despite this, the company has seen a fall of -24.93% in its stock price over the last five trading days. prnewswire.com reported 2024-11-07 that — Bempikibart Phase 2 topline results in atopic dermatitis (AD) and alopecia areata (AA) remain on-track for Q4’24, with topline data from both trials expected in December — — Enrollment ongoing in ADX-097 Phase 2 basket trial for complement mediated renal diseases, with topline data expected in 2H’25 and initial open-label data in 1H’25 — — Cash and cash equivalents of $89.1 million as of September 30, 2024 expected to provide financial runway through four Phase 2 clinical milestones and into mid-2026 — WALTHAM, Mass., Nov. 7, 2024 /PRNewswire/ — Q32 Bio Inc. (Nasdaq: QTTB) (“Q32 Bio”), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, today reported financial results for the quarter ended September 30, 2024, and provided recent corporate updates.
QTTB’s Market Performance
Q32 Bio Inc (QTTB) has experienced a -24.93% fall in stock performance for the past week, with a -28.75% drop in the past month, and a -3.47% drop in the past quarter. The volatility ratio for the week is 12.20%, and the volatility levels for the past 30 days are at 8.44% for QTTB. The simple moving average for the past 20 days is -22.95% for QTTB’s stock, with a 19.02% simple moving average for the past 200 days.
Analysts’ Opinion of QTTB
Many brokerage firms have already submitted their reports for QTTB stocks, with Raymond James repeating the rating for QTTB by listing it as a “Strong Buy.” The predicted price for QTTB in the upcoming period, according to Raymond James is $90 based on the research report published on October 24, 2024 of the current year 2024.
Wells Fargo, on the other hand, stated in their research note that they expect to see QTTB reach a price target of $95. The rating they have provided for QTTB stocks is “Overweight” according to the report published on September 11th, 2024.
Guggenheim gave a rating of “Buy” to QTTB, setting the target price at $100 in the report published on June 17th of the current year.
QTTB Trading at -22.64% from the 50-Day Moving Average
After a stumble in the market that brought QTTB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -33.76% of loss for the given period.
Volatility was left at 8.44%, however, over the last 30 days, the volatility rate increased by 12.20%, as shares sank -28.22% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -22.22% lower at present.
During the last 5 trading sessions, QTTB fell by -24.93%, which changed the moving average for the period of 200-days by +195.44% in comparison to the 20-day moving average, which settled at $46.24. In addition, Q32 Bio Inc saw 225.57% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at QTTB starting from TZIANABOS ARTHUR, who sale 265 shares at the price of $24.20 back on Mar 25 ’24. After this action, TZIANABOS ARTHUR now owns 7,983 shares of Q32 Bio Inc, valued at $6,413 using the latest closing price.
Alloway Paul, the of Q32 Bio Inc, sale 268 shares at $24.21 during a trade that took place back on Mar 25 ’24, which means that Alloway Paul is holding 2,596 shares at $6,488 based on the most recent closing price.
Stock Fundamentals for QTTB
Current profitability levels for the company are sitting at:
- -35.79 for the present operating margin
- 0.8 for the gross margin
The net margin for Q32 Bio Inc stands at -34.98. The total capital return value is set at -0.62. Equity return is now at value -93.26, with -40.61 for asset returns.
Based on Q32 Bio Inc (QTTB), the company’s capital structure generated 0.27 points at debt to capital in total, while cash flow to debt ratio is standing at -6.63. The debt to equity ratio resting at 0.37. The interest coverage ratio of the stock is -39.14.
Currently, EBITDA for the company is -86.5 million with net debt to EBITDA at 1.32. When we switch over and look at the enterprise to sales, we see a ratio of 191.6. The receivables turnover for the company is 3.3for trailing twelve months and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.53.
Conclusion
To wrap up, the performance of Q32 Bio Inc (QTTB) has been mixed in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
